KESTRA MEDICAL TECHNOLOGIES, LTD.
For the period ended Apr 30, 2026. Filed Jul 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jul 14, 2026
KMTS$30.12+4.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| ExhibitNumber | Description |
| 3.1 | Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 10, 2025 and incorporated herein by reference). |
| 3.2 | Memorandum of Association (previously filed as Exhibit 3.2 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 10, 2025 and incorporated herein by reference). |
| 3.3 | Amended and Restated Bye-laws of the Registrant (previously filed as Exhibit 3.1 to the Current Report on Form 8-K (File No. 001-42549) filed on March 7, 2025 and incorporated herein by reference). |
| 3.4 | Certificate of Deposit of Memorandum of Increase of Share Capital (previously filed as Exhibit 3.2 to the Current Report on Form 8-K (File No. 001-42549) filed on March 7, 2025 and incorporated herein by reference). |
| 4.1 | Warrant to Purchase 62,325 Common Shares issued to Kennedy Lewis Capital Partners Master Fund II LP, dated March 7, 2025, by and among Kestra Medical Technologies, Ltd., West Affum Holdings, L.P. and Kennedy Lewis Capital Partners Master Fund II LP (previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed on March 7, 2025 and incorporated herein by reference). |
| 4.2 | Warrant to Purchase 46,744 Common Shares issued to Kennedy Lewis Capital Partners Master Fund II LP, dated March 7, 2025, by and among Kestra Medical Technologies, Ltd., West Affum Holdings, L.P. and Kennedy Lewis Capital Partners Master Fund II LP (previously filed as Exhibit 10.2 to the Current Report on Form 8-K filed on March 7, 2025 and incorporated herein by reference). |
| 4.3 | Description of Share Capital (previously filed as Exhibit 4.4 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.1 | Assignment and Assumption of Registration Rights Agreement, dated as of February 26, 2025, by and between West Affum Holdings, L.P. and Kestra Medical Technologies, Ltd. (previously filed as Exhibit 10.1 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 26, 2025 and incorporated herein by reference). |
| 10.2 + | Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (previously filed as Exhibit 10.4 to the Current Report on Form 8-K filed on March 7, 2025 and incorporated herein by reference). |
| 10.3 + | Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan (previously filed as Exhibit 10.1 to the Quarterly Report on Form 10-Q on March 17, 2026 and incorporated herein by reference). |
| 10.4* | Loan Agreement, dated as of July 10, 2026, between Kestra Medical Technologies, Inc. and the guarantors signatory therein, BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP. |
| 10.5+ | Form of Indemnification Agreement (previously filed as Exhibit 10.4 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 26, 2025 and incorporated herein by reference). |
| 10.6+ | Employment Agreement, dated as of October 17, 2016, between Kestra Medical Technologies, Inc. and Brian Webster (previously filed as Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 10, 2025 and incorporated herein by reference). |
| 10.7+ | Employment Agreement, dated as of September 10, 2021, between Kestra Medical Technologies, Ltd. and Vaseem Mahboob (previously filed as Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 10, 2025 and incorporated herein by reference). |
| 10.8+ | Employment Agreement, dated as of October 26, 2016, between Kestra Medical Technologies, Inc. and Traci S. Umberger (previously filed as Exhibit 10.8 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 10, 2025 and incorporated herein by reference). |
| 10.9+ | Amendment to Employment Agreement, dated as of June 4, 2025, by and between Kestra Medical Technologies, Inc. and Brian Webster (previously filed as Exhibit 10.9 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.10+ | Amendment to Employment Agreement, dated as of June 4, 2025, by and between Kestra Medical Technologies, Inc. and Vaseem Mahboob (previously filed as Exhibit 10.10 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.11+ | Amendment to Employment Agreement, dated as of June 4, 2025, by and between Kestra Medical Technologies, Inc. and Traci S. Umberger (previously filed as Exhibit 10.11 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.12+ | Employment Agreement, dated as of June 4, 2025, by and between Kestra Medical Technologies, Inc. and Al Ford (previously filed as Exhibit 10.12 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.13+ | Employment Agreement, dated as of October 17, 2025, between Kestra Medical Technologies, Inc. and Timothy Moran (previously filed as Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on December 11, 2025 and incorporated herein by reference). |
| 10.14*+ | Kestra Medical Technologies, Ltd. Director Compensation Policy. |
| 10.15+ | Forms of Option Grant Notice under Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (previously filed as Exhibit 10.3 to Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-284807) filed on February 26, 2025 and incorporated herein by reference). |
| 10.16+ | Form of Restricted Stock Unit Grant Notice and Award Agreement (Non-employee Directors) under the Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (previously filed as Exhibit 10.13 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.17+ | Form of Restricted Stock Unit Grant Notice and Award Agreement (Executive Officers) under the Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (previously filed as Exhibit 10.14 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.18+ | Form of Performance Stock Unit Grant Notice and Award Agreement (revenue PSU) under the Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (previously filed as Exhibit 10.15 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 10.19+ | Form of Performance Stock Unit Grant Notice and Award Agreement (rTSR PSU) under the Kestra Medical Technologies, Ltd. 2025 Omnibus Incentive Plan (previously filed as Exhibit 10.16 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 19 | Insider Trading Policy of Kestra Medical Technologies, Ltd (previously filed as Exhibit 19 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 21 | List of Subsidiaries (previously filed as Exhibit 21 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 23* | Consent of Independent Registered Public Accounting Firm. |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 97 | Executive Compensation Recovery Policy (previously filed as Exhibit 97 to the Annual Report on Form 10-K filed on July 17, 2025 and incorporated herein by reference). |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- Filed herewith.
- Includes a management contract or compensatory plan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Kestra Medical Technologies, Ltd. | ||
| Date: July 14, 2026 | By: | /s/ Brian Webster |
|---|---|---|
| Brian Webster | ||
| President and Chief Executive Officer | ||
| Date: July 14, 2026 | By: | /s/ Vaseem Mahboob |
| Vaseem Mahboob | ||
| Chief Financial Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Brian Webster | President and Chief Executive Officer, and Director | July 14, 2026 |
| Brian Webster | (Principal Executive Officer) | |
| /s/ Vaseem Mahboob | Chief Financial Officer | July 14, 2026 |
| Vaseem Mahboob | (Principal Financial and Accounting Officer) | |
| /s/ Traci Umberger | General Counsel and CAO, and Director | July 14, 2026 |
| Traci Umberger | ||
| /s/ Jeff Schwartz | Chairman of the Board of Directors | July 14, 2026 |
| Jeff Schwartz | ||
| /s/ Raymond W. Cohen | Director | July 14, 2026 |
| Raymond W. Cohen | ||
| /s/ Mary Kay Ladone | Director | July 14, 2026 |
| Mary Kay Ladone | ||
| /s/ Kevin Reilly | Director | July 14, 2026 |
| Kevin Reilly | ||
| /s/ Conor Hanley | Director | July 14, 2026 |
| Conor Hanley | ||
| /s/ Elizabeth Kwo | Director | July 14, 2026 |
| Elizabeth Kwo | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID 238) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss | F-4 |
| Consolidated Statements of Changes in Redeemable Preferred Stock and Shareholders’ Equity (Deficit) | F-5 |
| Consolidated Statements of Cash Flows | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.